23andMe Holding Co. (ME) - Utang jangka dawa marang modal

23andme.com - logo grafis emiten ME

The market dynamics of 23andMe Holding Co. (ME) reflect the consequences of a deep crisis triggered by the failure of subscription services and the threat of bankruptcy, with the indicator standing at 0.93. This leader in genetic research relies on global authority in DNA diagnostics. The business is integrating sustainable components into its test kits and strictly protecting the privacy of biodata, merging scientific progress with the principles of sustainable development.

23andMe - Utang jangka dawa marang modal ME (periode 04.07.2022 - 05.04.2025)
Produk merek 23andMe Inc.

This indicator calculates the proportion of long-term borrowings relative to the organization's equity. The metric determines the business's degree of dependence on external financing and its long-term solvency. For 23andMe Holding Co. (ME), this is a critical marker due to the exhaustion of resources from the old sales model and a liquidity deficit. Restructuring requires strict control over borrowed capital. Analyzing the ratio of long-term liabilities to equity allows for an assessment of the company's bankruptcy risks.

Pesaing wigati

Rasio utang jangka dawa marang modal A (Agilent Technologies, Inc.)|Utang jangka dawa marang modal DGX|Utang jangka dawa marang modal Illumina Platform (ILMN)|Utang jangka dawa marang ekuitas Exact Sciences EXAS|RVTY: Rasio utang jangka dawa marang modal|Bio-Rad - Utang jangka dawa marang modal|NNNN - Utang jangka dawa marang modal|Sterigenics (SHC) - Utang jangka dawa marang ekuitas|QDEL (QuidelOrtho Inc.) - Utang jangka dawa marang ekuitas|Rasio utang jangka dawa marang ekuitas OPK|Kewajiban jangka dawa marang modal CareDx Corp CDNA|Utang jangka dawa marang ekuitas Maravai LifeSciences Holdings, Inc. (MRVI)|Rasio tanggungan utang jangka dawa marang modal Fulgent Genetics Inc|Utang jangka dawa marang modal LAB (Fluidigm)|Rasio tanggungan utang jangka dawa marang modal Cytek Corp (CTKB)|OSUR - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka dawa marang modal Exagen Inc. XGN|MDxHealth (MDXH) - Utang jangka dawa marang ekuitas|Rasio utang jangka dawa marang ekuitas Lucid Diagnostics, Inc.|PRE (Prenetics Global Limited) - Utang jangka dawa marang modal|Utang jangka dawa marang modal Insight Molecular|Utang jangka dawa marang ekuitas Trinity Biotech plc (TRIB)|prophaselabs.com - Rasio utang jangka dawa marang modal|Utang jangka dawa marang modal AIMD (Ainos)|CODX: Rasio utang jangka dawa marang modal|HSCS - Utang jangka dawa marang ekuitas|Biomerica Inc (BMRA) - Rasio utang jangka dawa marang ekuitas|CDIO: Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal viraxbiolabs.com (VRAX)|Rasio utang jangka dawa marang ekuitas BJDX|AWH: Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal AXDX|CNTG (Centogene) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Enzo Biochem ENZ|Fresh2 Group Ltd (FRES) - Kewajiban jangka dawa marang modal|GENE - Utang jangka dawa marang ekuitas|PMD: Utang jangka dawa marang ekuitas